Post by A.forall

Good news: we have expanded our US generic injectables portfolio with the FDA approval for Sodium Bicarbonate Injection. Through our US subsidiary, Milla Pharmaceuticals Inc., we are proud to share that we have received FDA approval (ANDA) for our Sodium Bicarbonate Injection, USP. This marks our 10th generic product in the United States and our second injectable designed to correct severe metabolic acidosis. 👉 Discover the full details of this milestone: https://lnkd.in/e3x8GJmH 📩 Contact the team: [email protected] #FocusToGrow #USHealthcare #GenericExcellence #Aforall #MillaPharmaceuticals